Cargando…

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells

The urokinase plasminogen activator receptor (uPAR) has been proposed as a potential prognostic factor for various malignancies. The aim of this study is to assess the prognostic value of uPAR expression in neoplastic and stromal cells of patients with pancreatic adenocarcinoma. Urokinase plasminoge...

Descripción completa

Detalles Bibliográficos
Autores principales: de Geus, Susanna WL, Baart, Victor M, Boonstra, Martin C, Kuppen, Peter JK, Prevoo, Hendrica AJM, Mazar, Andrew P, Bonsing, Bert A, Morreau, Hans, van de Velde, Cornelis JH, Vahrmeijer, Alexander L, Sier, Cornelis FM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484551/
https://www.ncbi.nlm.nih.gov/pubmed/28690396
http://dx.doi.org/10.1177/1177271917715443
_version_ 1783245902054424576
author de Geus, Susanna WL
Baart, Victor M
Boonstra, Martin C
Kuppen, Peter JK
Prevoo, Hendrica AJM
Mazar, Andrew P
Bonsing, Bert A
Morreau, Hans
van de Velde, Cornelis JH
Vahrmeijer, Alexander L
Sier, Cornelis FM
author_facet de Geus, Susanna WL
Baart, Victor M
Boonstra, Martin C
Kuppen, Peter JK
Prevoo, Hendrica AJM
Mazar, Andrew P
Bonsing, Bert A
Morreau, Hans
van de Velde, Cornelis JH
Vahrmeijer, Alexander L
Sier, Cornelis FM
author_sort de Geus, Susanna WL
collection PubMed
description The urokinase plasminogen activator receptor (uPAR) has been proposed as a potential prognostic factor for various malignancies. The aim of this study is to assess the prognostic value of uPAR expression in neoplastic and stromal cells of patients with pancreatic adenocarcinoma. Urokinase plasminogen activator receptor expression was determined by immunohistochemistry in 122 pancreatic ductal adenocarcinomas. Kaplan-Meier and Cox regression analyses were used to determine the association with survival. Respectively 66%, 82% and 62% of patients with pancreatic cancer expressed uPAR in neoplastic cells, stromal, and in both combined. Multivariate analysis showed a significant inverse association between uPAR expression in both neoplastic and stromal cells and overall survival. The prognostic impact of uPAR in stromal cells is substantial, but not as pronounced as that of uPAR expression in neoplastic cells. This study suggests a role for uPAR as a biomarker to single out higher risk subgroups of patients with pancreatic cancer.
format Online
Article
Text
id pubmed-5484551
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-54845512017-07-07 Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells de Geus, Susanna WL Baart, Victor M Boonstra, Martin C Kuppen, Peter JK Prevoo, Hendrica AJM Mazar, Andrew P Bonsing, Bert A Morreau, Hans van de Velde, Cornelis JH Vahrmeijer, Alexander L Sier, Cornelis FM Biomark Insights Review The urokinase plasminogen activator receptor (uPAR) has been proposed as a potential prognostic factor for various malignancies. The aim of this study is to assess the prognostic value of uPAR expression in neoplastic and stromal cells of patients with pancreatic adenocarcinoma. Urokinase plasminogen activator receptor expression was determined by immunohistochemistry in 122 pancreatic ductal adenocarcinomas. Kaplan-Meier and Cox regression analyses were used to determine the association with survival. Respectively 66%, 82% and 62% of patients with pancreatic cancer expressed uPAR in neoplastic cells, stromal, and in both combined. Multivariate analysis showed a significant inverse association between uPAR expression in both neoplastic and stromal cells and overall survival. The prognostic impact of uPAR in stromal cells is substantial, but not as pronounced as that of uPAR expression in neoplastic cells. This study suggests a role for uPAR as a biomarker to single out higher risk subgroups of patients with pancreatic cancer. SAGE Publications 2017-06-22 /pmc/articles/PMC5484551/ /pubmed/28690396 http://dx.doi.org/10.1177/1177271917715443 Text en © The Author(s) 2017 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
de Geus, Susanna WL
Baart, Victor M
Boonstra, Martin C
Kuppen, Peter JK
Prevoo, Hendrica AJM
Mazar, Andrew P
Bonsing, Bert A
Morreau, Hans
van de Velde, Cornelis JH
Vahrmeijer, Alexander L
Sier, Cornelis FM
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
title Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
title_full Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
title_fullStr Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
title_full_unstemmed Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
title_short Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
title_sort prognostic impact of urokinase plasminogen activator receptor expression in pancreatic cancer: malignant versus stromal cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484551/
https://www.ncbi.nlm.nih.gov/pubmed/28690396
http://dx.doi.org/10.1177/1177271917715443
work_keys_str_mv AT degeussusannawl prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT baartvictorm prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT boonstramartinc prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT kuppenpeterjk prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT prevoohendricaajm prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT mazarandrewp prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT bonsingberta prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT morreauhans prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT vandeveldecornelisjh prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT vahrmeijeralexanderl prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells
AT siercornelisfm prognosticimpactofurokinaseplasminogenactivatorreceptorexpressioninpancreaticcancermalignantversusstromalcells